The Adipokine-Cardiovascular-Lifestyle Network: Translation to Clinical Practice

Journal of the American College of Cardiology

Volumn 68, Issue 16, 2016, Pages 1785-1803

  Mechanick, Jeffrey I ^a   Zhao, Shan ^b   Garvey, W Timothy ^c,d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Telequire   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

cardiovascular disease; diabetes; hypertension; lifestyle medicine; network; obesity; systems biology

Indexed keywords

ADIPOCYTOKINE; BRANCHED CHAIN AMINO ACID; LEPTIN; MONOUNSATURATED FATTY ACID; OMEGA 3 FATTY ACID; POLYPHENOL; SOYBEAN PROTEIN; VITAMIN D;

BLOOD CLOTTING; BODY MASS; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CELL MIGRATION; FEEDING BEHAVIOR; HEART PROTECTION; HUMAN; HYPOXIA; INFLAMMATION; LIFESTYLE; LIFESTYLE MODIFICATION; MEDITERRANEAN DIET; METABOLIC SYNDROME X; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; SMOKING; THROMBOCYTE ACTIVATION; CARDIOVASCULAR DISEASES; CARDIOVASCULAR FUNCTION; PHYSIOLOGY;

ADIPOKINES; CARDIOVASCULAR DISEASES; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; HUMANS; LIFE STYLE; METABOLIC SYNDROME X; OBESITY;

EID: 84994504412     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.06.072     Document Type: Review

References (170)

1. 1 Barabási, A.L., Oltvai, Z.N., Network biology: understanding the cell's functional organization. Nat Rev Genet 5 (2004), 101–113.
2. 2 Zhao, S., Iyengar, R., Systems pharmacology: network analysis to identify multiscale mechanisms of drug action. Annu Rev Pharmacol Toxicol 52 (2012), 505–521.
3. 3 Fuster-Parra, P., Tauler, P., Bennasar-Veny, M., et al. Bayesian network modeling: a case study of an epidemiologic system analysis of cardiovascular risk. Comput Methods Programs Biomed 126 (2016), 128–142.
4. 4 Ding, J., Reynolds, L.M., Zeller, T., et al. Alterations of a cellular cholesterol metabolism network are a molecular feature of obesity-related type 2 diabetes and cardiovascular disease. Diabetes 64 (2015), 3464–3474.
5. 5 Valavanis, I.K., Mougiakakou, S.G., Grimaldi, K.A., Nikita, K.S., A multifactorial analysis of obesity as CVD risk factor: use of neural network based methods in a nutrigenetics context. BMC Bioinformatics, 11, 2010, 453.
6. 6 Landgraf, K., Rockstroh, D., Wagner, I.V., et al. Evidence of early alterations in adipose tissue biology and function and its association with obesity-related inflammation and insulin resistance in children. Diabetes 64 (2015), 1249–1261.
7. 7 Garvey, W.T., Garber, A.J., Mechanick, J.I., et al., for the AACE Obesity Scientific Committee. American Association of Clinical Endocrinologists and American College of Endocrinology consensus conference on obesity: building an evidence base for comprehensive action. Endocr Pract 20 (2014), 956–976.
8. 8 American Medical Association House of Delegates. Resolution 420: Recognition of Obesity as a Disease. 2013, American Medical Association, Chicago, IL Available at: http://www.npr.org/documents/2013/jun/ama-resolution-obesity.pdf.
9. 9 Sperling, L.S., Mechanick, J.I., Neeland, I.J., et al. The CardioMetabolic Health Alliance: working toward a new care model for the metabolic syndrome. J Am Coll Cardiol 66 (2015), 1050–1067.
10. 10 Gaggini, M., Saponaro, C., Gastaldelli, A., Not all fats are created equal: adipose vs. ectopic fat, implication in cardiometabolic diseases. Horm Mol Biol Clin Investig 22 (2015), 7–18.
11. 11 Lehr, S., Hartwig, S., Sell, H., Adipokines: a treasure trove for the discovery of biomarkers for metabolic disorders. Proteomics Clin Appl 6 (2012), 91–101.
12. 12 Castoldi, A., Naffah de Souza, C., Câmara, N.O., Moraes-Vieira, P.M., The macrophage switch in obesity development. Front Immunol, 6, 2016, 637.
13. 13 Nakamura, K., Fuster, J.J., Walsh, K., Adipokines: a link between obesity and cardiovascular disease. J Cardiol 63 (2014), 250–259.
14. 14 Mechanick, J.I., Kushner, R.F., Why lifestyle medicine?. Mechanick, J.I., Kushner, R.F., (eds.) Lifestyle Medicine: A Manual for Clinical Practice, 2016, Springer, New York, NY, 1–8.
15. 15 Ellis, G.F., Top-down causation and emergence: some comments on mechanisms. Interface Focus 2 (2012), 126–140.
16. 16 Mattu, H.S., Randeva, H.S., Role of adipokines in cardiovascular disease. J Endocrinol 216 (2013), T17–T36.
17. 17 Freitas Lima, L.C., Braga, V.A., do Socorro de França Silva, M., et al. Adipokines, diabetes and atherosclerosis: an inflammatory association. Front Physiol, 6, 2015, 304.
18. 18 Blüher, M., Adipokines—removing road blocks to obesity and diabetes therapy. Mol Metab 3 (2014), 230–240.
19. 19 Zuckerkandl, E., Pauling, L., Evolutionary divergence and convergence in proteins. Bryson, V., Vogel, H.J., (eds.) Evolving Genes and Proteins: A Symposium, 1965, Academic Press, New York, NY, 97–166.
20. 20 Tamura, K., Stecher, G., Peterson, D., Filipski, A., Kumar, S., MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. Mol Biol Evol 30 (2013), 2725–2729.
21. 21 Wist, A.D., Berger, S.I., Iyengar, R., Systems pharmacology and genome medicine: a future perspective. Genome Med, 1, 2009, 11.
22. 22 Ashburner, M., Ball, C.A., Blake, J.A., et al., for the Gene Ontology Consortium. Gene ontology: tool for the unification of biology. Nat Genet 25 (2000), 25–29.
23. 23 Zhao, S., Nishimura, T., Chen, Y., et al. Systems pharmacology of adverse event mitigation by drug combinations. Sci Transl Med, 5, 2013, 206ra140.
24. 24 Berger, S.I., Posner, J.M., Ma'ayan, A., Genes2Networks: connecting lists of gene symbols using mammalian protein interactions databases. BMC Bioinformatics, 8, 2007, 372.
25. 25 Berger, S.I., Ma'ayan, A., Iyengar, R., Systems pharmacology of arrhythmias. Sci Signal, 3, 2010, ra30.
26. 26 Wasserman, S., Faust, K., Social Network Analysis: Methods and Applications. 1994, Cambridge University Press, Cambridge, UK.
27. 27 Pujol, A., Mosca, R., Farrés, J., Aloy, P., Unveiling the role of network and systems biology in drug discovery. Trends Pharmacol Sci 31 (2010), 115–123.
28. 28 Greenblum, S., Turnbaugh, P.J., Borenstein, E., Metagenomic systems biology of the human gut microbiome reveals topological shifts associated with obesity and inflammatory bowel disease. Proc Natl Acad Sci U S A 109 (2012), 594–599.
29. 29 CARDIoGRAMplusC4D Consortium, Deloukas, P., Kanoni, S., et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet 45 (2013), 25–33.
30. 30 Tao, W., Xu, X., Wang, X., et al. Network pharmacology-based prediction of the active ingredients and potential targets of Chinese herbal Radix Curcumae formula for application to cardiovascular disease. J Ethnopharmacol 145 (2013), 1–10.
31. 31 Long, Q., Argmann, C., Houten, S.M., et al., for the GTEx Consortium. Inter-tissue coexpression network analysis reveals DPP4 as an important gene in heart to blood communication. Genome Med, 8, 2016, 15.
32. 32 Huan, T., Zhang, B., Wang, Z., et al. A systems biology framework identifies molecular underpinnings of coronary heart disease. Arterioscler Thromb Vasc Biol 33 (2013), 1427–1434.
33. 33 Heinig, M., Petretto, E., Wallace, C., et al. A trans-acting locus regulates an anti-viral expression network and type 1 diabetes risk. Nature 467 (2010), 460–464.
34. 34 Breitling, R., Robust signaling networks of the adipose secretome. Trends Endocrinol Metab 20 (2009), 1–7.
35. 35 Chen, X., Target network analysis of adiponectin, a multifaceted adipokine. J Cell Biochem 114 (2013), 1145–1152.
36. 36 Oga, E.A., Eseyin, O.R., The obesity paradox and heart failure: a systematic review of a decade of evidence. J Obes, 2016, 2016, 9040248.
37. 37 Lavie, C.J., De Schutter, A., Parto, P., et al. Obesity and prevalence of cardiovascular diseases and prognosis—the obesity paradox updated. Prog Cardiovasc Dis 58 (2016), 537–547.
38. 38 Flegal, K.M., Kit, B.K., Orpana, H., Graubard, B.I., Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA 309 (2013), 71–82.
39. 39 Mechanick, J.I., “What if” being overweight was good for you?. Endocr Pract 19 (2013), 166–168.
40. 40 Sweeney, G., Cardiovascular effects of leptin. Nat Rev Cardiol 7 (2010), 22–29.
41. 41 Antonopoulos, A.S., Antoniades, C., Tousoulis, D., Unravelling the “adipokine paradox”: when the classic proatherogenic adipokine leptin is deemed the beneficial one. Int J Cardiol 197 (2015), 125–127.
42. 42 Sharma, S., Colangelo, L.A., Allison, M.A., et al. Association of serum leptin with future left ventricular structure and function: the Multi-Ethnic Study of Atherosclerosis (MESA). Int J Cardiol 193 (2015), 64–68.
43. 43 McGaffin, K.R., Moravec, C.S., McTiernan, C.F., Leptin signaling in the failing and mechanically unloaded human heart. Circ Heart Fail 2 (2009), 676–683.
44. 44 Wannamethee, S.G., Shaper, A.G., Whincup, P.H., Lennon, L., Papacosta, O., Sattar, N., The obesity paradox in men with coronary heart disease and heart failure: the role of muscle mass and leptin. Int J Cardiol 171 (2014), 49–55.
45. 45 Leifheit-Nestler, M., Wagner, N.M., Gogiraju, R., et al. Importance of leptin signaling and signal transducer and activator of transcription-3 activation in mediating the cardiac hypertrophy associated with obesity. J Transl Med, 11, 2013, 170.
46. 46 Hascoet, S., Elbaz, M., Bongard, V., et al. Adiponectin and long-term mortality in coronary artery disease participants and controls. Arterioscler Thromb Vasc Biol 33 (2013), e19–e29.
47. 47 Wu, Z.J., Cheng, Y.J., Gu, W.J., et al. Adiponectin is associated with increased mortality in patients with already established cardiovascular disease: a systematic review and meta-analysis. Metabolism 63 (2014), 1157–1166.
48. 48 Berg, G., Schreier, L., Miksztowicz, V., Circulating and adipose tissue matrix metalloproteinases in cardiometabolic risk environments: pathophysiological aspects. Horm Mol Biol Clin Investig 17 (2014), 79–87.
49. 49 Jernås, M., Olsson, B., Sjöholm, K., et al. Changes in adipose tissue gene expression and plasma levels of adipokines and acute-phase proteins in patients with critical illness. Metabolism 58 (2009), 102–108.
50. 50 Bilkovski, R., Schulte, D.M., Oberhauser, F., et al. Adipose tissue macrophages inhibit adipogenesis of mesenchymal precursor cells via wnt-5a in humans. Int J Obes (Lond) 35 (2011), 1450–1454.
51. 51 Miyoshi, T., Doi, M., Usui, S., et al. Low serum level of secreted frizzled-related protein 5, an anti-inflammatory adipokine, is associated with coronary artery disease. Atherosclerosis 233 (2014), 454–459.
52. 52 Dalzell, J.R., Rocchiccioli, J.P., Weir, R.A., et al. The emerging potential of the apelin-APJ system in heart failure. J Card Fail 21 (2015), 489–498.
53. 53 Wildman, R.P., Muntner, P., Reynolds, K., et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999–2004). Arch Intern Med 168 (2008), 1617–1624.
54. 54 Alfadda, A.A., Circulating adipokines in healthy versus unhealthy overweight and obese subjects. Int J Endocrinol, 2014, 2014, 170434.
55. 55 Guo, F., Garvey, W.T., Cardiometabolic disease risk in metabolically healthy and unhealthy obesity: stability of metabolic health status in adults. Obesity (Silver Spring) 24 (2016), 516–525.
56. 56 Indulekha, K., Surendar, J., Anjana, R.M., et al. Metabolic obesity, adipocytokines, and inflammatory markers in Asian Indians—CURES-124. Diabetes Technol Ther 17 (2015), 134–141.
57. 57 Romero-Corral, A., Somers, V.K., Sierra-Johnson, J., et al. Normal weight obesity: a risk factor for cardiometabolic dysregulation and cardiovascular mortality. Eur Heart J 31 (2010), 737–746.
58. 58 Marques-Vidal, P., Pécoud, A., Hayoz, D., et al. Normal weight obesity: relationship with lipids, glycaemic status, liver enzymes and inflammation. Nutr Metab Cardiovasc Dis 20 (2010), 669–675.
59. 59 Ahl, S., Guenther, M., Zhao, S., et al. Adiponectin levels differentiate metabolically healthy vs unhealthy among obese and nonobese white individuals. J Clin Endocrinol Metab 100 (2015), 4172–4180.
60. 60 Guenther, M., James, R., Marks, J., Zhao, S., Szabo, A., Kidambi, S., Adiposity distribution influences circulating adiponectin levels. Transl Res 164 (2014), 270–277.
61. 61 Ferrer, R., Pardina, E., Rossell, J., et al. Morbidly “healthy” obese are not metabolically healthy but less metabolically imbalanced than those with type 2 diabetes or dyslipidemia. Obes Surg 25 (2015), 1380–1391.
62. 62 Gómez-Ambrosi, J., Catalán, V., Rodríguez, A., et al. Increased cardiometabolic risk factors and inflammation in adipose tissue in obese subjects classified as metabolically healthy. Diabetes Care 37 (2014), 2813–2821.
63. 63 Pereira, S., Teixeira, L., Aguilar, E., et al. Modulation of adipose tissue inflammation by FOXP3+ Treg cells, IL-10, and TGF-β in metabolically healthy class III obese individuals. Nutrition 30 (2014), 784–790.
64. 64 Heilbronn, L.K., Campbell, L.V., Xu, A., Samocha-Bonet, D., Metabolically protective cytokines adiponectin and fibroblast growth factor-21 are increased by acute overfeeding in healthy humans. PLoS One, 8, 2013, e78864.
65. 65 Mechanick JI, Cobin RH, Einhorn D, et al. American College of Endocrinology/American Association of Clinical Endocrinologists: reaffirmation of the 2003 ACE insulin resistance syndrome (IRS) position statement. American Association of Clinical Endocrinologists. Inc. 2005. Available at: https://www.aace.com/files/position-statements/irsstatement.pdf. Accessed August 4, 2016.
66. 66 Srikanthan, K., Feyh, A., Visweshwar, H., Shapiro, J.I., Sodhi, K., Systematic review of metabolic syndrome biomarkers: a panel for early detection, management, and risk stratification in the West Virginian population. Int J Med Sci 13 (2016), 25–38.
67. 67 López-Jaramillo, P., Gómez-Arbeláez, D., López-López, J., et al. The role of leptin/adiponectin ratio in metabolic syndrome and diabetes. Horm Mol Biol Clin Investig 18 (2014), 37–45.
68. 68 Grundy, S.M., Adipose tissue and metabolic syndrome: too much, too little or neither. Eur J Clin Invest 45 (2015), 1209–1217.
69. 69 Klöting, N., Blüher, M., Adipocyte dysfunction, inflammation and metabolic syndrome. Rev Endocr Metab Disord 15 (2014), 277–287.
70. 70 Rubio-Ruiz, M.E., Peredo-Escárcega, A.E., Cano-Martínez, A., Guarner-Lans, V., An evolutionary perspective of nutrition and inflammation as mechanisms of cardiovascular disease. Int J Evol Biol, 2015, 2015, 179791.
71. 71 Belalcazar, L.M., Lang, W., Haffner, S.M., et al., for the Look AHEAD (Action for Health in Diabetes) Research Group. Improving adiponectin levels in individuals with diabetes and obesity: insights from Look AHEAD. Diabetes Care 38 (2015), 1544–1550.
72. 72 Hjorth, M.F., Damsgaard, C.T., Michaelsen, K.F., Astrup, A., Sjodin, A., Markers of metabolic health in children differ between weekdays—the result of unhealthier weekend behavior. Obesity (Silver Spring) 23 (2015), 733–736.
73. 73 Fenk, S., Fischer, M., Strack, C., et al. Successful weight reduction improves left ventricular diastolic function and physical performance in severe obesity. Int Heart J 56 (2015), 196–202.
74. 74 Sahin-Efe, A., Polyzos, S.A., Dincer, F., et al. Intracellular leptin signaling following effective weight loss. Metabolism 64 (2015), 888–895.
75. 75 Chuang, C.C., Martinez, K., Xie, G., et al. Quercetin is equally or more effective than resveratrol in attenuating tumor necrosis factor-α-mediated inflammation and insulin resistance in primary human adipocytes. Am J Clin Nutr 92 (2010), 1511–1521.
76. 76 Sáinz, N., González-Navarro, C.J., Martínez, J.A., Moreno-Aliaga, M.J., Leptin signaling as a therapeutic target of obesity. Expert Opin Ther Targets 19 (2015), 893–909.
77. 77 Gomes, P.M., Hollanda-Miranda, W.R., Beraldo, R.A., et al. Supplementation of α-linolenic acid improves serum adiponectin levels and insulin sensitivity in patients with type 2 diabetes. Nutrition 31 (2015), 853–857.
78. 78 Richard, C., Royer, M.M., Couture, P., et al. Effect of the Mediterranean diet on plasma adipokine concentrations in men with metabolic syndrome. Metabolism 62 (2013), 1803–1810.
79. 79 Jaakkola, J.M., Pahkala, K., Viitala, M., et al. Association of adiponectin with adolescent cardiovascular health in a dietary intervention study. J Pediatr 167 (2015), 353–360.e1.
80. 80 Waterhouse, M., Tran, B., Ebeling, P.R., et al. Effect of vitamin D supplementation on selected inflammatory biomarkers in older adults: a secondary analysis of data from a randomised, placebo-controlled trial. Br J Nutr 114 (2015), 693–699.
81. 81 Newbern, D., Gumus Balikcioglu, P., Balikcioglu, M., et al. Sex differences in biomarkers associated with insulin resistance in obese adolescents: metabolomic profiling and principal components analysis. J Clin Endocrinol Metab 99 (2014), 4730–4739.
82. 82 König, D., Zdzieblik, D., Deibert, P., Berg, A., Gollhofer, A., Buchert, M., Internal fat and cardiometabolic risk factors following a meal-replacement regimen vs. comprehensive lifestyle changes in obese subjects. Nutrients 7 (2015), 9825–9833.
83. 83 Lara-Castro, C., Garvey, W.T., Diet, insulin resistance, and obesity: zoning in on data for Atkins dieters living in South Beach. J Clin Endocrinol Metab 89 (2004), 4197–4205.
84. 84 Serrano-Martinez, M., Palacios, M., Martinez-Losa, E., et al. A Mediterranean dietary style influences TNF-alpha and VCAM-1 coronary blood levels in unstable angina patients. Eur J Nutr 44 (2005), 348–354.
85. 85 Urpi-Sarda, M., Casas, R., Chiva-Blanch, G., et al. Virgin olive oil and nuts as key foods of the Mediterranean diet effects on inflammatory biomakers related to atherosclerosis. Pharmacol Res 65 (2012), 577–583.
86. 86 Yubero-Serrano, E.M., Gonzalez-Guardia, L., Rangel-Zuñiga, O., et al. Mediterranean diet supplemented with coenzyme Q10 modifies the expression of proinflammatory and endoplasmic reticulum stress-related genes in elderly men and women. J Gerontol A Biol Sci Med Sci 67 (2012), 3–10.
87. 87 Jobs, E., Adamsson, V., Larsson, A., et al. Influence of a prudent diet on circulating cathepsin S in humans. Nutr J, 13, 2014, 84.
88. 88 Barry, V.W., Baruth, M., Beets, M.W., Durstine, J.L., Liu, J., Blair, S.N., Fitness vs. fatness on all-cause mortality: a meta-analysis. Prog Cardiovasc Dis 56 (2014), 382–390.
89. 89 Lavie, C.J., De Schutter, A., Milani, R.V., Healthy obese versus unhealthy lean: the obesity paradox. Nat Rev Endocrinol 11 (2015), 55–62.
90. 90 Poelkens, F., Eijsvogels, T.M., Brussee, P., Verheggen, R.J., Tack, C.J., Hopman, M.T., Physical fitness can partly explain the metabolically healthy obese phenotype in women. Exp Clin Endocrinol Diabetes 122 (2014), 87–91.
91. 91 Rambhojan, C., Bouaziz-Amar, E., Larifla, L., et al. Ghrelin, adipokines, metabolic factors in relation with weight status in school-children and results of a 1-year lifestyle intervention program. Nutr Metab (Lond), 12, 2015, 43.
92. 92 Apostolopoulos, V., Borkoles, E., Polman, R., Stojanovska, L., Physical and immunological aspects of exercise in chronic diseases. Immunotherapy 6 (2014), 1145–1157.
93. 93 Stanford, K.I., Middelbeek, R.J., Goodyear, L.J., Exercise effects on white adipose tissue: beiging and metabolic adaptations. Diabetes 64 (2015), 2361–2368.
94. 94 Ozcan, O., Bostanci, M.Ö., Cicek, G., Yamaner, F., The effects of two different exercise programmes on adipose tissue hormones in sedentary middle-aged women. Arch Physiol Biochem 121 (2015), 50–55.
95. 95 Metcalf, B.S., Jeffery, A.N., Hosking, J., Voss, L.D., Sattar, N., Wilkin, T.J., Objectively measured physical activity and its association with adiponectin and other novel metabolic markers: a longitudinal study in children (EarlyBird 38). Diabetes Care 32 (2009), 468–473.
96. 96 Neuparth, M.J., Proença, J.B., Santos-Silva, A., Coimbra, S., The positive effect of moderate walking exercise on chemerin levels in Portuguese patients with type 2 diabetes mellitus. J Investig Med 62 (2014), 350–353.
97. 97 Kim, S.H., Lee, S.H., Ahn, K.Y., et al. Effect of lifestyle modification on serum chemerin concentration and its association with insulin sensitivity in overweight and obese adults with type 2 diabetes. Clin Endocrinol (Oxf) 80 (2014), 825–833.
98. 98 Stieg, M.R., Sievers, C., Farr, O., Stalla, G.K., Mantzoros, C.S., Leptin: a hormone linking activation of neuroendocrine axes with neuropathology. Psychoneuroendocrinology 51 (2015), 47–57.
99. 99 Danese, A., Dove, R., Belsky, D.W., et al. Leptin deficiency in maltreated children. Transl Psychiatry, 4, 2014, e446.
100. 100 Strollo, F., Vassilieva, G., Ruscica, M., et al. Changes in stress hormones and metabolism during a 105-day simulated Mars mission. Aviat Space Environ Med 85 (2014), 793–797.
101. 101 Jaremka, L.M., Belury, M.A., Andridge, R.R., et al. Interpersonal stressors predict ghrelin and leptin levels in women. Psychoneuroendocrinology 48 (2014), 178–188.
102. 102 Wagner, L., Kaestner, F., Wolf, R., et al. Identifying neuropeptide Y (NPY) as the main stress-related substrate of dipeptidyl peptidase 4 (DPP4) in blood circulation. Neuropeptides 57 (2016), 21–34.
103. 103 Hofmann, T., Ahnis, A., Elbelt, U., Rose, M., Klapp, B.F., Stengel, A., NUCB2/nesfatin-1 is associated with elevated levels of anxiety in anorexia nervosa. PLoS One, 10, 2015, e0132058.
104. 104 Navarro-Solera, M., Carrasco-Luna, J., Pin-Arboledas, G., Gonzalez-Carrascosa, R., Soriano, J.M., Codoner-Franch, P., Short sleep duration is related to emerging cardiovascular risk factors in obese children. J Pediatr Gastroenterol Nutr 61 (2015), 571–576.
105. 105 Mota, M.C., Waterhouse, J., De-Souza, D.A., et al. Sleep pattern is associated with adipokine levels and nutritional markers in resident physicians. Chronobiol Int 31 (2014), 1130–1138.
106. 106 Olson, C.A., Hamilton, N.A., Somers, V.K., Percentage of REM sleep is associated with overnight change in leptin. J Sleep Res 25 (2016), 419–425.
107. 107 Al Mutairi, S., Mojiminiyi, O.A., Al Alawi, A., Al Rammah, T., Abdella, N., Study of leptin and adiponectin as disease markers in subjects with obstructive sleep apnea. Dis Markers, 2014, 2014, 706314.
108. 108 Xu, T., Lin, Y., Sun, S., Zjang, Q., Changes in four plasma adipokines before and after sleep in OSAS patients. Clin Respir J, 2016 Jan 8 [E-pub ahead of print].
109. 109 Chen, X., Niu, X., Xiao, Y., Dong, J., Lu, M., Kong, W., Effect of continuous positive airway pressure on leptin levels in patients with obstructive sleep apnea: a meta-analysis. Otolaryngol Head Neck Surg 152 (2015), 610–618.
110. 110 Corgosinho, F.C., Ackel-D'Elia, C., Tufik, S., et al. Beneficial effects of a multifaceted 1-year lifestyle intervention on metabolic abnormalities in obese adolescents with and without sleep-disordered breathing. Metab Syndr Relat Disord 13 (2015), 110–118.
111. 111 Potretzke, S., Nakajima, M., Cragin, T., al'Absi, M., Changes in circulating leptin levels during acute stress and associations with craving in abstinent smokers: a preliminary investigation. Psychoneuroendocrinology 47 (2014), 232–240.
112. 112 al'Absi, M., Lemieux, A., Nakajima, M., Hatsukami, D.K., Allen, S., Circulating leptin and pain perception among tobacco-dependent individuals. Biol Psychol 107 (2015), 10–15.
113. 113 Chełchowska, M., Ambroszkiewicz, J., Mazur, J., et al. Effect of tobacco smoking on the maternal and fetal adipokine axis in relation to newborn birth weight and length. Przegla̧d Lek 71 (2014), 567–571.
114. 114 Kotani, K., Hazama, A., Hagimoto, A., et al. Adiponectin and smoking status: a systematic review. J Atheroscler Thromb 19 (2012), 787–794.
115. 115 Inoue, K., Takeshima, F., Kadota, K., et al. Early effects of smoking cessation and weight gain on plasma adiponectin levels and insulin resistance. Intern Med 50 (2011), 707–712.
116. 116 Al Mutairi, S.S., Mojiminiyi, O.A., Shihab-Eldeen, A., Al Rammah, T., Abdella, N., Putative roles of circulating resistin in patients with asthma, COPD and cigarette smokers. Dis Markers 31 (2011), 1–7.
117. 117 Messner, B., Bernhard, D., Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis. Arterioscler Thromb Vasc Biol 34 (2014), 509–515.
118. 118 Zhu, X., Gerstein, M., Snyder, M., Getting connected: analysis and principles of biological networks. Genes Dev 21 (2007), 1010–1024.
119. 119 Ma'ayan, A., Jenkins, S.L., Neves, S., et al. Formation of regulatory patterns during signal propagation in a mammalian cellular network. Science 309 (2005), 1078–1083.
120. 120 NCBI. Gene [online database]. Bethesda, MD: National Center for Biotechnology Information. 2005–2016. Available at: https://www.ncbi.nlm.nih.gov/gene. Accessed August 5, 2016.
121. 121 Stojanović, S., Ilić, M.D., Ilić, S., Petrovic, D., Djukic, S., The significance of adiponectin as a biomarker in metabolic syndrome and/or coronary artery disease. Vojnosanit Pregl 72 (2015), 779–784.
122. 122 Takeuchi, M., Tsuboi, A., Kurata, M., Fukuo, K., Kazumi, T., Association of metabolic syndrome with serum adipokines in community-living elderly Japanese women: independent association with plasminogen activator-inhibitor-1. Metab Syndr Relat Disord 13 (2015), 415–421.
123. 123 Teng, M.S., Hsu, L.A., Wu, S., Sun, Y.C., Juan, S.H., Ko, Y.L., Association of CDH13 genotypes/haplotypes with circulating adiponectin levels, metabolic syndrome, and related metabolic phenotypes: the role of the suppression effect. PLoS One, 10, 2015, e0122664.
124. 124 Zhang, X., Li, D., Wang, H., Pang, C., Wu, Y., Wen, F., Gender difference in plasma fatty-acid-binding protein 4 levels in patients with chronic obstructive pulmonary disease. Biosci Rep, 36, 2016, e00302.
125. 125 Kim, J.Y., Yadav, D., Ahn, S.V., Koh, S.B., A prospective study of serum adiponectin and regression of metabolic syndrome: the ARIRANG study. Biochem Biophys Res Commun 466 (2015), 201–205.
126. 126 Sun, Y., Li, D.G., Li, Q., et al. Relationship between ADIPOQ gene polymorphism and lipid levels and diabetes. J Biol Regul Homeost Agents 29 (2015), 221–227.
127. 127 Legakis, I., Mantzouridis, T., Bouboulis, G., Chrousos, G.P., Reciprocal changes of serum adispin and visfatin levels in patients with type 2 diabetes after an overnight fast. Arch Endocrinol Metab 60 (2016), 76–78.
128. 128 Poveda, N.E., Garcés, M.F., Ruiz-Linares, C.E., et al. Serum adipsin levels throughout normal pregnancy and preeclampsia. Sci Rep, 6, 2016, 20073.
129. 129 Zeng, Z.Y., Gui, C., Li, L., Wei, X.M., Effects of percutaneous coronary intervention on serum angiopoietin-2 in patients with coronary heart disease. Chin Med J (Engl) 129 (2016), 631–635.
130. 130 Sato, A., Iwama, A., Takakura, N., Nishio, H., Yancopoulos, G.D., Suda, T., Characterization of TEK receptor tyrosine kinase and its ligands, angiopoietins, in human hematopoietic progenitor cells. Int Immunol 10 (1998), 1217–1227.
131. 131 Yu, N., Zhang, Y.Y., Niu, X.Y., et al. Evaluation of shear wave velocity and human bone morphogenetic protein-7 for the diagnosis of diabetic kidney disease. PLoS One, 10, 2015, e0119713.
132. 132 Liu, F., Ventura, F., Doody, J., Massaque, J., Human type II receptor for bone morphogenic proteins (BMPs): extension of the two-kinase receptor model to the BMPs. Mol Cell Biol 15 (1995), 3479–3486.
133. 133 ten Dijke, P., Yamashita, H., Sampath, T.K., et al. Identification of type I receptors for osteogenic protein-1 and bone morphogenetic protein-4. J Biol Chem 269 (1994), 16985–16988.
134. 134 Li, X., Li, Y., Jin, J., et al. Increased serum cathepsin K in patients with coronary artery disease. Yonsei Med J 55 (2014), 912–919.
135. 135 Sukhova, G.K., Shi, G.P., Simon, D.I., Chapman, H.A., Libby, P., Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest 102 (1998), 576–583.
136. 136 Jialal, I., Devaraj, S., Kaur, H., et al. Increased chemerin and decreased omentin-1 in both adipose tissue and plasma in nascent metabolic syndrome. J Clin Endocrinol Metab 98 (2013), E514–E517.
137. 137 Mehanna, E.T., Mesbah, N.M., Ghattas, M.H., Saleh, S.M., Abo-Elmatty, D.M., Association of chemerin Rs17173608 and vaspin Rs2236242 gene polymorphisms with metabolic syndrome in Egyptian women. Endocr Res 41 (2016), 43–48.
138. 138 Zheng, T., Gao, Y., Baskota, A., Chen, T., Ran, X., Tian, H., Increased plasma DPP4 activity is predictive of prediabetes and type 2 diabetes onset in Chinese over a four-year period: result from the China National Diabetes and Metabolic Disorders Study. J Clin Endocrinol Metab 99 (2014), E2330–E2334.
139. 139 Buelt, M.K., Shekels, L.L., Jarvis, B.W., Bernlohr, D.A., In vitro phosphorylation of the adipocyte lipid-binding protein (p15) by the insulin receptor. Effects of fatty acid on receptor kinase and substrate phosphorylation. J Biol Chem 266 (1991), 12266–12271.
140. 140 Shen, W.J., Sridhar, K., Bernlohr, D.A., Kraemer, F.B., Interaction of rat hormone-sensitive lipase with adipocyte lipid-binding protein. Proc Natl Acad Sci U S A 96 (1999), 5528–5532.
141. 141 Srinivas, P.R., Wagner, A.S., Reddy, L.V., et al. Serum alpha 2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level. Mol Endocrinol 7 (1993), 1445–1455.
142. 142 Sugars, R.V., Waddington, R.J., Embery, G., The interaction of recombinant decorin with alpha2HS-glycoprotein–implications for structural and functional investigations. Protein Expr Purif 25 (2002), 180–188.
143. 143 Stenvinkel, P., Wang, K., Qureshi, A.R., et al. Low fetuin-A levels are associated with cardiovascular death: impact of variations in the gene encoding fetuin. Kidney Int 67 (2005), 2383–2392.
144. 144 Di Iorio, A., Ferrucci, L., Sparvieri, E., et al. Serum IL-1beta levels in health and disease: a population-based study: “The InCHIANTI study.”. Cytokine 22 (2003), 198–205.
145. 145 Vigers, G.P., Anderson, L.J., Caffes, P., Brandhuber, B.J., Crystal structure of the type-I interleukin-1 receptor complexed with interleukin-1beta. Nature 386 (1997), 190–194.
146. 146 Webb, D.J., Gonias, S.L., A modified human alpha 2-macroglobulin derivative that binds tumor necrosis factor-alpha and interleukin-1 beta with high affinity in vitro and reverses lipopolysaccharide toxicity in vivo in mice. Lab Invest 78 (1998), 939–948.
147. 147 Ito, A., Mukaiyama, A., Itoh, Y., et al. Degradation of interleukin 1β by matrix metalloproteinases. J Biol Chem 271 (1996), 14657–14660.
148. 148 Velarde, G.P., Sherazi, S., Kraemer, D.F., et al. Clinical and biochemical markers of cardiovascular structure and function in women with the metabolic syndrome. Am J Cardiol 116 (2015), 1705–1710.
149. 149 Boumaiza, I., Omezzine, A., Rejeb, J., et al. Relationship between leptin G2548A and leptin receptor Q223R gene polymorphisms and obesity and metabolic syndrome risk in Tunisian volunteers. Genet Test Mol Biomarkers 16 (2012), 726–733.
150. 150 Ariza, X., Graupera, I., Coll, M., et al. for the CANONIC Investigators, EASL CLIF Consortium. Neutrophil gelatinase-associated lipocalin is a biomarker of acute-on-chronic liver failure and prognosis in cirrhosis. J Hepatol 65 (2016), 57–65.
151. 151 Kjeldsen, L., Johnsen, A.H., Sengeløv, H., Borregaard, N., Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 268 (1993), 10425–10432.
152. 152 Coles, M., Diercks, T., Muehlenweg, B., et al. The solution structure and dynamics of human neutrophil gelatinase-associated lipocalin. J Mol Biol 289 (1999), 139–157.
153. 153 Gwira, J.A., Wei, F., Ishibe, S., Ueland, J.M., Barasch, J., Cantley, L.G., Expression of neutrophil gelatinase-associated lipocalin regulates epithelial morphogenesis in vitro. J Biol Chem 280 (2005), 7875–7882.
154. 154 Aksu, O., Aydın, B., Doguç, D.K., et al. The evaluation of Nesfatin-1 levels in patients with OSAS associated with metabolic syndrome. J Endocrinol Invest 38 (2015), 463–469.
155. 155 Zhang, Z., Li, L., Yang, M., Liu, H., Boden, G., Yang, G., Increased plasma levels of nesfatin-1 in patients with newly diagnosed type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 120 (2012), 91–95.
156. 156 Qu, H., Deng, H., Hu, Z., Plasma progranulin concentrations are increased in patients with type 2 diabetes and obesity and correlated with insulin resistance. Mediators Inflamm, 2013, 2013, 360190.
157. 157 Hoque, M., Young, T.M., Lee, C.G., Serrero, G., Mathews, M.B., Pe'ery, T., The growth factor granulin interacts with cyclin T1 and modulates P-TEFb-dependent transcription. Mol Cell Biol 23 (2003), 1688–1702.
158. 158 Baladrón, V., Ruiz-Hidalgo, M.J., Bonvini, E., et al. The EGF-like homeotic protein Dlk affects cell growth and interacts with growth-modulating molecules in the yeast two-hybrid system. Biochem Biophys Res Commun 291 (2002), 193–204.
159. 159 Bobbert, P., Weithäuser, A., Andres, J., et al. Increased plasma retinol binding protein 4 levels in patients with inflammatory cardiomyopathy. Eur J Heart Fail 11 (2009), 1163–1168.
160. 160 Fex, G., Hansson, B., Retinol-binding protein from human urine and its interaction with retinol and prealbumin. Eur J Biochem 94 (1979), 307–313.
161. 161 Hinterhuber, G., Cauza, K., Brugger, K., et al. RPE65 of retinal pigment epithelium, a putative receptor molecule for plasma retinol-binding protein, is expressed in human keratinocytes. J Invest Dermatol 122 (2004), 406–413.
162. 162 Raghu, P., Ravinder, P., Sivakumar, B., A new method for purification of human plasma retinol-binding protein and transthyretin. Biotechnol Appl Biochem 38 (2003), 19–24.
163. 163 Blann, A.D., Wang, J.M., Wilson, P.B., Kumar, S., Serum levels of the TGF-beta receptor are increased in atherosclerosis. Atherosclerosis 120 (1996), 221–226.
164. 164 Lin, H.Y., Moustakas, A., Knaus, P., Wells, R.G., Henis, Y.I., Lodish, H.F., The soluble exoplasmic domain of the type II transforming growth factor (TGF)-beta receptor: a heterogeneously glycosylated protein with high affinity and selectivity for TGF-β ligands. J Biol Chem 270 (1995), 2747–2754.
165. 165 Dobaczewski, M., Chen, W., Frangogiannis, N.G., Transforming growth factor (TGF)-β signaling in cardiac remodeling. J Mol Cell Cardiol 51 (2011), 600–606.
166. 166 Dimova, R., Tankova, T., The role of vaspin in the development of metabolic and glucose tolerance disorders and atherosclerosis. Biomed Res Int, 2015, 2015, 823481.
167. 167 Arakawa, H., Ikeda, U., Hojo, Y., et al. Decreased serum vascular endothelial growth factor concentrations in patients with congestive heart failure. Heart 89 (2003), 207–208.
168. 168 Gerhardt, H., Golding, M., Fruttiger, M., et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 161 (2003), 1163–1177.
169. 169 Jenkins, A.J., Joglekar, M.V., Hardikar, A.A., Keech, A.C., O'Neal, D.N., Januszewski, A.S., Biomarkers in diabetic retinopathy. Rev Diabet Stud 12 (2015), 159–195.
170. 170 Nourbakhsh, M., Nourbakhsh, M., Gholinejad, Z., Razzaghy-Azar, M., Visfatin in obese children and adolescents and its association with insulin resistance and metabolic syndrome. Scand J Clin Lab Invest 75 (2015), 183–188.